PRIMARY CUTANEOUS DLBCL, LEG TYPE
Clinical trials for PRIMARY CUTANEOUS DLBCL, LEG TYPE explained in plain language.
Never miss a new study
Get alerted when new PRIMARY CUTANEOUS DLBCL, LEG TYPE trials appear
Sign up with your email to follow new studies for PRIMARY CUTANEOUS DLBCL, LEG TYPE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New targeted therapy combo aims to boost remission in Tough-to-Treat lymphoma
Disease control CompletedThis Phase 3 trial tested whether adding the targeted drug polatuzumab vedotin to a standard chemotherapy regimen (R-ICE) helps people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study enrolled 306 adults whose lymphoma had come back or did not respond …
Matched conditions: PRIMARY CUTANEOUS DLBCL, LEG TYPE
Phase: PHASE3 • Sponsor: GWT-TUD GmbH • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
CAR T-Cell therapy shows promise against tough lymphoma in major trial
Disease control CompletedThis phase 3 trial tested whether a personalized cell therapy called axicabtagene ciloleucel (Yescarta) works better than standard chemotherapy for people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The study enrolled 359 participants and compared event-fre…
Matched conditions: PRIMARY CUTANEOUS DLBCL, LEG TYPE
Phase: PHASE3 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC